Republicans take aim at funding mechanism for Affordable Care Act
GOP champions out-of-state policies in health care reform
Plecanatide replicates function of uroguanylin
President Obama expected to sign far-reaching legislation
Slightly more than half say health care coverage is Washington’s responsibility
Hospitals must supply both verbal and written notification to patients
Chronic therapy increases risks of harmful consequences, including death

P&T December 2016
Table of Contents


A final rule from the Centers for Medicare and Medicaid Services has added pharmacy requirements for long-term-care facilities that put more responsibility on pharmacists but don’t address conflict-of-interest concerns.
Pharmacovigilance Forum
Rituximab can cause late-onset neutropenia that may result in serious life-threatening complications. The author describes the pathophysiology, incidence, and management of this adverse reaction and presents two case histories.
The authors review the evidence behind the use of thrombolytic therapy in patients with massive or submassive pulmonary embolism. Concurrent heparin therapy and the management of bleeding episodes are also discussed.
Short on funds and with no therapeutics or vaccines in sight, U.S. health officials are scrambling to prepare for a protracted fight with Zika virus and the mosquitoes that carry it. In this article, the author focuses on the arrival of Zika in the U.S.
Meeting Highlights
We review several key sessions from the European Society for Medical Oncology’s annual congress, including those on emerging immunotherapies for melanoma and non–small-cell lung cancer and on treatments for renal, ovarian, and breast cancer.
Season’s Greetings


Prescription: Washington
Medicare names plans for Part D MTM demo
Approvals, new indications, regulatory activities, and more
Lisinopril oral solution (Qbrelis) for the treatment of hypertension, heart failure, and acute myocardial infarction; etanercept-szzs (Erelzi) for multiple autoimmune disorders; and lumacaftor/ivacaftor (Orkambi) for cystic fibrosis
Drug Forecast
Daclatasvir (Daklinza) for chronic hepatitis C infection


Regorafenib Safe for Older Colorectal Cancer Patients

Eric Van Cutsem, MD, discusses a subgroup analysis involving patients 75 years of age and older in the Consign study of regorafenib for treatment-refractory metastatic colorectal cancer. The analysis found no major differences in safety compared with younger patients as long as the patients were fit enough to be eligible for treatment—so age itself is no reason to withhold regorafenib.

ESMO World Congress on Gastrointestinal Cancer, June 29–July 2, 2016